Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy

Nutritional Supplementation, Diet, and Genetics and Their Impact on Parkinson’s Disease (PD), a Review of Studies

“…The results of the study showed that tHcy was elevated in both levodopatreated and untreated PD compared to the controls. 47 The findings indicated that MTHFR C677T was a key factor in the occurrence of hyperhomocysteinemia in patients with Parkinson's disease, regardless of levodopa treatment status.…”

“…A study conducted by Todorovic et al, 47 sought to clarify whether Levodopa treatment was necessary for homocysteine serum levels in PD patients with MTHFR C677T genotype. The total level of homocysteine (tHcy) and MTHFR C677T in serum were investigated in both PD patients who were treated and those not treated with levodopa, as well as healthy controls matched by gender and age.…”

Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects

“…42 Interestingly, homocysteine and its metabolites (ie, methylmalonate or cystatin C) have been suggested to be increased in PD, since the time of the diagnosis.…”

Pharmacogenetics and the Treatment of Thrombophilia

“…The expansion of pharmacogenetics, the study of genetic variants relevant to variations in drug efficacy and toxicity, and pharmacogenomics, referred to as a whole-genome application of pharmacogenetics, allowed rapid progress towards the goal of personalized therapy, tailored for individual patients [14][15][16][17].…”